Monte Rosa Earnings Estimate

GLUE Stock  USD 19.57  0.02  0.10%   
By analyzing Monte Rosa's earnings estimates, investors can diagnose different trends across Monte Rosa's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Monte Rosa Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Monte Rosa is projected to generate -0.34535 in earnings per share on the 31st of December 2026. Monte Rosa earnings estimates show analyst consensus about projected Monte Rosa Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Monte Rosa's historical volatility. Many public companies, such as Monte Rosa, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Monte Rosa's earnings estimates, investors can diagnose different trends across Monte Rosa's analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 81.5 M, whereas Pretax Profit Margin is forecasted to decline to (0.88). Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Monte Rosa Earnings per Share Projection vs Actual

About Monte Rosa Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Monte Rosa earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Monte Rosa estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Monte Rosa fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-394.7 M-375 M
Retained Earnings Total Equity-207.5 M-217.9 M
Earnings Yield(0.16)(0.17)
Price Earnings Ratio(6.35)(6.67)
Price Earnings To Growth Ratio 0.10  0.11 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
0.32
Revenue Per Share
2.208
Quarterly Revenue Growth
0.385
Return On Assets
0.0137
Return On Equity
0.0928
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.